U.S. markets closed
  • S&P Futures

    4,167.00
    -9.25 (-0.22%)
     
  • Dow Futures

    34,009.00
    -72.00 (-0.21%)
     
  • Nasdaq Futures

    13,997.50
    -32.00 (-0.23%)
     
  • Russell 2000 Futures

    2,253.60
    -5.40 (-0.24%)
     
  • Crude Oil

    62.92
    -0.21 (-0.33%)
     
  • Gold

    1,777.70
    -2.50 (-0.14%)
     
  • Silver

    26.02
    -0.08 (-0.33%)
     
  • EUR/USD

    1.1976
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3822
    -0.0018 (-0.13%)
     
  • USD/JPY

    108.6950
    -0.0880 (-0.08%)
     
  • BTC-USD

    56,096.06
    -5,260.18 (-8.57%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Insulet to Announce Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2020 on February 23, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at http://investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 6384566.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.myomnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005057/en/

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Jason McGorman
Principal Investor Relations Analyst
(978) 600-7627
jmcgorman@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com